Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Serena Mazzucchelli1, Michela Bellini2, Luisa Fiandra1, Marta Truffi1, Maria A. Rizzuto2, Luca Sorrentino1, Erika Longhi1, Manuela Nebuloni1, Davide Prosperi2, Fabio Corsi1, 3 1Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy 2Department of Biotechnology and Biosciences, University of Milan-Bicocca, Milano, Italy 3Surgery Department, Breast Unit, ICS Maugeri S. p. A. SB, Pavia, Italy Correspondence to: Fabio Corsi, email: fabio.corsi@unimi.it Davide Prosperi, email: davide.prosperi@unimib.it Keywords: metronomic chemotherapy, breast cancer, doxorubicin, drug resistance, tumor targeting Received: October 07, 2016 Accepted: November 24, 2016 Published: December 25, 2016